Zalekta Public Company Limited

As of June 30, 2026, Zalekta Public Company Limited NVDR carries a market capitalization of 1.10B, placing it among publicly traded companies globally. Its enterprise value stands at 968.91M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Zalekta Public Company Limited NVDR has 650.06M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 9.47, and the price-to-book ratio stands at 5.03.

These figures are as of June 30, 2026. The EV/Sales ratio of 8.36 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 968.91M versus a market cap of 1.10B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Zalekta Public Company Limited NVDR maintains a current ratio of 6.98, meaning it holds 7.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.87, indicating elevated leverage, while an interest coverage ratio of -36.95 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Zalekta Public Company Limited NVDR posted a negative return on equity (ROE) of -20.28, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -17.52, reflecting losses generated across the asset base. The company generates approximately 2.83M in revenue per employee across its workforce of 41.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1,062.15 indicates how many times Zalekta Public Company Limited NVDR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Zalekta Public Company Limited NVDR recorded 587,604.00 in income tax expense. The company reported a pretax loss of -45.69M and -49.32M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Zalekta Public Company Limited NVDR's stock has declined approximately 12.71% over the past 52 weeks. The 50-day moving average sits at 1.59, while the 200-day moving average is 1.73.

Over the twelve months ended June 30, 2026, Zalekta Public Company Limited NVDR generated 115.95M in revenue and converted that into -49.32M in net income, yielding earnings per share of -0.07. EBITDA reached -38.62M, while operating income came in at -31.11M.

As of June 30, 2026, Zalekta Public Company Limited NVDR holds 148.86M in cash and equivalents against 11.05M in total debt, resulting in a net debt position of -148.86M. Total book value stands at 218.51M, with working capital of 147.50M providing operational flexibility.

Zalekta Public Company Limited NVDR produced -25.98M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.78M in capital expenditures, free cash flow totaled -30.76M - equivalent to -0.05 per share.

Over the twelve months ended June 30, 2026, Zalekta Public Company Limited NVDR posted a gross margin of 34.50, reflecting its pricing power and cost economics. The operating margin of -26.83 and net profit margin of -42.53 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -2.80: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.21, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zalekta Public Company Limited NVDR shareholders.

Zalekta Public Company Limited NVDR's most recent stock split took place on May 26, 2025 with a 2:1 split ratio.

As of June 30, 2026, Zalekta Public Company Limited NVDR has an Altman Z-Score of 18.21, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.